Robert W. Baird Boosts Immutep (NASDAQ:IMMP) Price Target to $7.00

Immutep (NASDAQ:IMMP) had its price target lifted by Robert W. Baird from $6.00 to $7.00 in a report released on Friday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.

Immutep Stock Down 3.9 %

IMMP stock opened at $1.97 on Friday. The company has a fifty day moving average price of $2.10 and a two-hundred day moving average price of $2.32. Immutep has a one year low of $1.58 and a one year high of $3.34. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Immutep

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMMP. XTX Topco Ltd bought a new position in Immutep in the second quarter valued at about $26,000. BNP Paribas Financial Markets increased its position in Immutep by 15.4% in the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 4,700 shares during the period. XY Capital Ltd bought a new position in shares of Immutep during the second quarter valued at $105,000. Virtu Financial LLC lifted its holdings in shares of Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares during the period. Finally, Meridian Wealth Management LLC grew its stake in shares of Immutep by 4.5% in the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after purchasing an additional 17,250 shares during the last quarter. 2.32% of the stock is currently owned by institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.